London
· Delayed Price · Currency is GBP · Price in USD Adverum Biotechnologies Company Description
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2006 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 121 |
| CEO | Laurent Fischer |
Contact Details
Address: 100 Cardinal Way Redwood City, Delaware 94063 United States | |
| Phone | 650 656 9323 |
| Website | adverum.com |
Stock Details
| Ticker Symbol | 0HA3 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Laurent Fischer | Chief Executive Officer |
| Linda Rubinstein | Chief Financial Officer |
| Kishor Soparkar | Chief Operating Officer |